A mixed-methods evaluation of the quantitative and perceived impact of Brexit on UK oncology clinical trial initiation between 2011 and 2020.

J Pharm Policy Pract · 2026 · PMC13270869 · PMID 42311631

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an overall trendno p-value reported

It could be suggested that the decline observed here cannot be attributed only to Phase 3 trials in the UK, and may be a reflection of an overall trend in clinical trial initiation.

also in 4,871 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.